Lyra Therapeutics (LYRA)
NASDAQ:LYRA
US Market

Lyra Therapeutics (LYRA) Stock Price & Analysis

132 Followers

LYRA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.35 - $8.18
Previous Close$2.75
Volume34.86K
Average Volume (3M)33.27K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$109.56M
Total Debt (Recent Filing)$657.00K
Price to Earnings (P/E)-1.0
Beta-1.12
Next EarningsMar 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-2.79
Shares Outstanding31,827,008
R-Squared0.02
Standard Deviation0.19
10 Day Avg. Volume33,964
30 Day Avg. Volume33,273
Price to Book (P/B)0.97
Price to Sales (P/S)68.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
Alpha-0.03
Number of Analyst Covering0


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

LYRA FAQ

What was Lyra Therapeutics’s price range in the past 12 months?
Lyra Therapeutics lowest stock price was $2.35 and its highest was $8.18 in the past 12 months.
    What is Lyra Therapeutics’s market cap?
    Currently, no data Available
    When is Lyra Therapeutics’s upcoming earnings report date?
    Lyra Therapeutics’s upcoming earnings report date is Mar 08, 2023 which is in 30 days.
      How were Lyra Therapeutics’s earnings last quarter?
      Lyra Therapeutics released its earnings results on Nov 15, 2022. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.44 by $0.04.
        Is Lyra Therapeutics overvalued?
        According to Wall Street analysts Lyra Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Lyra Therapeutics pay dividends?
          Lyra Therapeutics does not currently pay dividends.
          What is Lyra Therapeutics’s EPS estimate?
          Lyra Therapeutics’s EPS estimate is -$0.42.
            How many shares outstanding does Lyra Therapeutics have?
            Lyra Therapeutics has 31,827,007 shares outstanding.
              What happened to Lyra Therapeutics’s price movement after its last earnings report?
              Lyra Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.44. Following the earnings report the stock price went down -2.5%.
                Which hedge fund is a major shareholder of Lyra Therapeutics?
                Among the largest hedge funds holding Lyra Therapeutics’s share is Perceptive Advisors LLC. It holds Lyra Therapeutics’s shares valued at 46M.

                  ---

                  Lyra Therapeutics Stock Smart Score

                  3
                  Underperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -33.57%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -77.86%
                  Trailing 12-Months
                  Asset Growth
                  76.30%
                  Trailing 12-Months
                  The Lyra Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Lyra Therapeutics

                  Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Paratek Pharmaceuticals
                  Trevi Therapeutics
                  Omeros
                  IMARA

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis